PharmaCyte Boosts Cash with Femasys Sale
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 26 Nov 25
Source: Newsfilter
PharmaCyte Biotech Inc has successfully monetized its stake in Femasys, increasing its cash and marketable securities from $13.3 million to approximately $20 million. This move significantly enhances the company's financial stability and investment capacity.
CEO Josh Silverman emphasized that this monetization validates the company's strategic approach to capital allocation. PharmaCyte plans to continue pursuing value-accretive investment opportunities to enhance shareholder returns.
Despite this positive development, PharmaCyte's stock price has fallen by 7.83% during regular trading, indicating cautious market sentiment regarding its long-term value, even as broader indices like the Nasdaq-100 and S&P 500 show gains.
Analyst Views on PMCB
About PMCB
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
